CD276 and diffuse midline glioma: A phase 1 clinical trial initiated to test the safety and efficacy of SC-CAR4BRAIN (NCT05768880) targeting B7-H3, EGFR806, HER2, and IL13, a CAR T cell therapy, in children and young adults with DIPG, diffuse midline glioma (DMG), and recurrent or refractory central nervous system (CNS) tumors plans to enroll 72 patients with a primary completion date of 15 January 2028.